Skip to content
newprotein.net Explore ingredients
Menu
Illustrated cut-away fermentation vessel with filtration and spray drying of protein powder

Precision fermentation: process, scale-up and regulation explained

Guide to precision fermentation and biomass fermentation for food protein: hosts, process steps, specifications, scale-up limits, allergens and regulation.

By the New Protein editorial team · Reviewed · 13 min read

Three routes to protein by fermentation

Fermentation covers three very different production routes, and buyers lose time when they treat them as one. Traditional fermentation transforms whole foods with living cultures. Biomass fermentation grows microbial cells as the food itself. Precision fermentation programmes a microbe to make one defined protein, which is then purified. Each route carries its own specifications, regulation and cost structure.

Traditional fermentation is the oldest and least regulated route. Soy and wheat proteins have long featured in Asian diets, as the Singapore Food Agency notes, and fermented foods rely on microbes that either remain in the product or are removed by cooking. These foods have a long history of use, so they rarely need novel food approval.

Biomass fermentation sits in the middle. Mycoprotein from Fusarium venenatum is the established example, and single-cell proteins from bacteria and yeast follow the same logic: grow cells quickly on a simple feedstock, harvest them, and process the biomass into a protein-rich ingredient. The cells are the product, so composition, nucleic acid content and digestibility become central questions.

Precision fermentation differs because the cell is a factory rather than the food. A host receives a gene that codes for a target such as beta-lactoglobulin, ovalbumin or leghemoglobin, secretes the protein into the broth, and is then removed. Review authors describe it as a livestock-free route to high-value proteins, but note that productivity and scale-up costs limit adoption today.

The route you choose follows the job to be done. Bulk, textured protein for meat analogues suits biomass. Functional or flavour-active proteins that are scarce in nature, such as whey proteins, egg white proteins or heme, suit precision fermentation. Combining routes in one product, such as a mycoprotein base with recombinant heme, is common.

Organisms and expression hosts

Host selection drives yield, purity and regulatory ease. Reviews of recombinant protein production in yeasts cover Saccharomyces cerevisiae, Komagataella phaffii (Pichia pastoris), Yarrowia lipolytica and the Kluyveromyces species, praising their ability to grow on inexpensive carbon sources and secrete complex proteins. Filamentous fungi such as Trichoderma reesei are also used, especially where very high secretion capacity is needed.

Real examples show the pattern. GRAS Notice 863 describes beta-lactoglobulin made by a genetically modified Trichoderma reesei, while the EFSA file on soy leghemoglobin covers a Komagataella phaffii strain, MXY0541, carrying the soy LGB2 coding sequence. Both hosts have long histories in industrial enzyme or protein production, which helps regulators judge the safety of the recipient organism.

Bacteria and microalgae serve other niches. Gas-fermenting bacteria such as Cupriavidus necator grow on elements found in the air and are explored for whole-cell protein, and the alga Euglena gracilis is produced by fermentation, although its dried biomass is mostly beta-glucan rather than protein. Hosts differ in how much regulatory history supports them.

Strain engineering decides economics as much as the fermenter. A 2025 review of recombinant technology in the food industry highlights CRISPR, vector integration and fermentation strategy as levers for yield and purity, and warns that aggregation and misfolding must be avoided to retain activity. For buyers, the practical questions are who owns the strain and how changes are controlled.

Some products need more than a good host. Post-translational modifications, such as glycosylation or removal of signal peptides, differ between yeast, fungi and animal cells. A study of fermentation-derived beta-lactoglobulin found that the mature protein carried an N-terminal extension of EAEA residues, which changed thermal behaviour. Such details can improve or degrade functionality, so they belong in the technical file.

How precision fermentation works step by step

A typical process starts with a seed fermenter. GRN 863 describes a lyophilised stock vial of the production strain starting each batch, with production moving from seed to main fermenter under cGMP controls and periodic checks that confirm strain identity and exclude foreign organisms. The same discipline applies to every host: defined media, controlled pH, aeration and batch records.

Secretion makes recovery simpler. In the beta-lactoglobulin process, the protein is secreted and remains dissolved in the fermentation medium, so recovery begins with solid-liquid centrifugation to separate biomass from broth. A pH adjustment step then concentrates the protein, an optional filtration and polishing step removes impurities, and ultrafiltration and diafiltration prepare it for spray drying.

Raw materials matter for compliance. The notifier of GRN 863 states that raw materials, processing aids, antifoams and pH adjusters meet predefined standards, including the Food Chemicals Codex 11th edition. Buyers should audit media components too, since a nitrogen source or antifoam can introduce allergens or contaminants that never show up in the target protein assay.

Drying and formulation finish the process. Spray drying yields a white to off-white powder in the GRN 863 file, with the product specified at more than 90 percent beta-lactoglobulin as a share of protein. Other ingredients may be sold as concentrates or liquids, so storage, water activity, particle size and solubility specifications need agreeing at the point of purchase.

Process changes require control. Singapore allows regulators to cancel approval after a material change to the production method or other application information, and a buyer relying on a dossier should expect similar logic elsewhere. Contracts should oblige the supplier to notify strain, medium and downstream changes in advance and share comparability data before shipping new lots.

Scale-up: titers, oxygen transfer and cost

Titer, rate and yield define the economics. A 2026 review on designing scalable systems states that low volumetric productivity and yield have historically driven costs up, and that linear scale-up often fails in large fermenters because of technical and operational constraints. It argues for scalability-first thinking, early techno-economic analysis and attention to existing infrastructure and co-location near feedstocks.

Engineering limits arise from physics. A review of yeast production at industrial scale discusses dissolved oxygen, pH, substrate concentration and temperature as the control parameters that change with scale, and points to cooling capacity and oxygen limitation as the challenges that intensification strategies must address. Cells that perform well in a 10 litre vessel can underperform in 100,000 litres.

Capital intensity pushes producers towards shared infrastructure. Many early-stage companies cannot afford dedicated fermenters, so they rent capacity from contract manufacturers that already run food or enzyme processes. This lowers entry cost but limits freedom to adjust the process, and it puts suppliers in competition for the same tanks, so capacity planning belongs in every sourcing plan.

Downstream processing often decides cost as much as upstream. Centrifugation, membrane filtration, polishing and drying all cost energy and yield, and each step must meet food standards for cleaning and microbial control. The Liu review notes that scaling microbial production to industrial level presents economic, efficiency and environmental challenges that require better strain screening and genome editing tools.

Price expectations should stay realistic. Review authors frame cost and functional parity with animal proteins as the condition for broad adoption and describe it as unmet for most targets. Buyers can expect premium prices for niche proteins and should model blends, where a small dose of a functional protein delivers most of the benefit, instead of full replacement.

Biomass fermentation and gas fermentation

Mycoprotein shows how biomass can reach consumers. A 2019 symposium review describes it as a nutritious nonmeat protein from the fungus Fusarium venenatum, sold in 17 countries and high in protein and fibre but low in fat, cholesterol, sodium and sugar. See the mycoprotein page for composition, and the comparison of mycoprotein and soy protein for formulation trade-offs.

Allergy risk exists but is described as low. A 2003 case report identified an acidic ribosomal protein, Fus c 1, that cross-reacts with a mould allergen and explained severe reactions in a mould-allergic patient who ate mycoprotein, while the 2019 review states that a systematic evidence review found reactions exceptionally rare. Declare the fungal origin clearly and expect advisory statements.

Euglena shows a different biomass outcome. EFSA describes dried whole-cell Euglena gracilis as produced by fermentation, with more than 50 percent beta-glucan, and judged it safe at the proposed uses, citing qualified presumption of safety, a no-observed-adverse-effect level of 3,300 mg per kg body weight and margins of exposure from 33 for infants to 192 for adults.

Gas fermentation offers a feedstock-independent path. Protein powder from heat-treated Cupriavidus necator, a bacterium that uses elements found in the air, passed genotoxicity tests and a 90-day rat study with no adverse effects up to 3,000 mg per kg body weight per day. Buyers still need nucleic acid, heavy metal and flavour specifications for whole-cell material.

Single-cell proteins from yeast and bacteria deserve scrutiny of nucleic acid content, cell wall digestibility and flavour. The related pages on single-cell protein and yeast protein list typical composition and regulatory status, and show that each organism needs its own dossier rather than a general claim covering all microbial protein.

Specifications and quality tests for fermentation-derived proteins

Identity and purity tests come first. The GRN 863 specification uses protein by Dumas or Kjeldahl above 85 percent by weight, protein on a dry matter basis above 90 percent, beta-lactoglobulin as a share of protein above 90 percent by HPLC and densitometry, moisture below 6 percent, ash below 3 percent, fat below 1.5 percent and carbohydrates below 2 percent.

Batch data show what to expect. Three non-consecutive lots in the notice reported Dumas protein of 94.1, 97.2 and 96.3 percent, beta-lactoglobulin at 99.5 to 100 percent of protein, moisture between 1 and 4.1 percent and ash of 1 to 1.3 percent. Ask any supplier for equivalent batch tables, and for the analytical methods that stand behind the numbers.

Host-derived impurities need limits. The GRN 863 file reports residual Trichoderma reesei proteins of up to 6.7 percent in one sample, and notes that the dominant residual proteins were cell wall related. Specifications for residual host protein, residual DNA, endotoxin, antibiotic residues and mycotoxins from fungal hosts should be explicit, with methods that are validated in the final matrix.

Microbiology and heavy metals follow food norms. Regulators routinely ask for limits on total plate count, yeasts and moulds, Enterobacteriaceae, Salmonella, lead, arsenic, cadmium and mercury, and the GRN 863 correspondence shows FDA requesting pH, heavy metal and microbial limits. Buyers should insist on certificates from accredited laboratories for every batch rather than periodic skip testing.

Functional tests should mimic your process. A 2026 study found fermentation-derived beta-lactoglobulin remained translucent and showed no detectable aggregation at 140 degrees Celsius, while the milk protein aggregated by 80 to 90 percent within 30 seconds. If your product undergoes UHT or retort treatment, run viscosity, turbidity and gel strength trials, because identical sequences may not behave identically.

Allergens, residual host protein and safety

Allergen status follows protein identity. The GRN 863 notice states that the notified beta-lactoglobulin is chemically identical to the milk protein, will produce a milk allergy in sensitised people, and will be labelled accordingly. It also confirms that no materials derived from other major allergens are used in production, and no major allergen apart from milk is present.

Host proteins create a second allergen question. Regulators ask whether residual host proteins, which reached several percent in some preparations, could trigger reactions. The GRN 863 notice reports analysis of residual proteins and argues they present no allergenicity concern. Expect similar questions for any host, and prepare bioinformatic and analytical evidence on residual proteins and DNA.

Safety assessments combine several lines of evidence. For soy leghemoglobin, EFSA’s additives panel found that heme iron from proposed uses was comparable to that from similar amounts of meat, that components are digested to peptides, amino acids and heme B, that the recipient strain qualifies for presumption of safety, and that no genotoxicity concern or numerical intake limit was needed.

Genetic modification triggers its own review in the EU. The GMO panel examined the molecular characterisation and bioinformatic data for the Komagataella phaffii strain and concluded that the leghemoglobin preparation is safe for human consumption regarding the genetic modification, with no environmental impact expected from residual recombinant DNA. A supplier should be able to point to this kind of assessment.

For biomass products, cell composition adds hazards. Whole-cell materials contain nucleic acids and cell wall components, and some strains produce toxins under stress, so toxicological studies such as the 90-day rat study on Cupriavidus necator protein are standard. Buyers should check that studies used material comparable to the commercial product, and that heavy metals, mycotoxins and solvent residues are specified.

Regulation of precision fermentation and other fermentation-derived proteins by region

In the European Union, products generally need a novel food authorisation, and the Union list under Regulation (EU) 2017/2470 records the conditions of use, labelling and specifications for each authorised entry. The Commission notes that authorisations are generic unless the applicant has requested data protection. Precision-fermented proteins made with genetically modified hosts may also fall under GMO rules.

EU examples show the process in practice. The Union list includes dried Euglena gracilis (2020/1820) and beta-glucan from Euglena (2024/1046). The leghemoglobin file was evaluated by both the additives panel under Regulation 1331/2008 and the GMO panel under Regulation 1829/2003. Each dossier answered different questions, so applicants plan parallel timelines and expect lengthy evaluation.

In the United States, the common route is a GRAS notification. The Perfect Day notice for beta-lactoglobulin from Trichoderma reesei, GRN 863, received a response of no questions from FDA, and the inventory lists closure on 25 March 2020. A no-questions letter is not an approval and addresses the notified conditions of use, so read the notice scope.

Singapore applies a pre-market approval framework. Novel food means food with no significant history of use for at least 20 years, and the agency names alternative proteins produced by precision fermentation as examples. Applicants submit safety assessments, a 13-member expert group advises, and from 28 November 2025 supplying such food without approval is an offence.

Other jurisdictions are evolving, and buyers should avoid assuming equivalence. A product cleared by a GRAS notice is not automatically authorised in the EU, and neither equals approval in Singapore. Each market has its own definitions of novel food, labelling of allergens and genetically modified production strains, and this guide makes no claim about regions that it did not source.

Sourcing precision fermentation ingredients and contract manufacturing

Sourcing begins with the strain. Ask who owns the production host, whether it is licensed, and how many generations the supplier has banked, because a supplier that cannot produce a master cell bank record or a strain history poses an identity risk. Request the recipient organism’s safety record and whether it holds qualified presumption of safety status for production.

The second screen is capacity. Reviews recommend using existing fermentation infrastructure to lower costs, which means many producers outsource to contract manufacturers. Ask where fermentation and downstream processing take place, whether the contractor handles other allergens, what cleaning validation exists, and how much volume is reserved for your supply. Dual sites reduce risk but increase the cost of comparability work.

Contracts should address change control and dossier ownership. Require advance notice of changes to strain, media, scale, equipment or site, comparability data for each, and shared access to regulatory dossiers where the law permits. Specify who owns data generated for authorisations, and who bears the cost of repeat studies if a regulator requests more information after launch.

Price negotiation should reflect process maturity. Early-stage ingredients priced at a premium justify blends in which a small share of a recombinant protein improves a function such as foaming, gelation or emulsification, with a cheaper base protein carrying bulk. For related products, compare the precision-fermented whey page with the comparison of precision-fermented whey and dairy whey.

Other targets follow similar patterns. Precision-fermented egg white faces the scientific and technological challenges that a 2025 review summarises as still in their infancy, and leghemoglobin is the most advanced heme source. Use each ingredient page to compare specification ranges, and ask suppliers to document how they differ from the benchmark protein.

Which route fits which product

For meat analogues, mycoprotein or other biomass supplies bulk, fibre and texture, while recombinant heme supplies colour and flavour. Combining them requires attention to allergens, since fungal and yeast proteins add their own, and to labelling of genetically modified production hosts in markets that require it. Check the compatibility of heme with the product’s pH, heat treatment and ingredients.

For dairy alternatives, recombinant whey proteins can add foaming, gelling and heat stability that plant proteins struggle to deliver. They remain milk allergens and carry a premium. A formulator might replace part of a plant protein with a precision-fermented milk protein, then validate heat stability, mouthfeel and shelf life in the final matrix, because the cost-benefit depends on dose.

For bakery and egg replacements, recombinant ovalbumin offers functional properties of egg white, but the egg protein field is early and cost-sensitive according to published reviews. Product developers should test plant alternatives alongside, such as potato, pea or chickpea proteins, and use fermentation-derived proteins where their functional advantage justifies the price and allergen labelling.

Decision-making benefits from a staged plan. Start with a desk review of regulatory status in the target market, request technical files from two or three suppliers, run bench trials at three inclusion levels, test thermal stability and allergen labelling, and confirm capacity before committing. The outcome is a defensible choice of route, supplier and dose.

Frequently asked questions

What is precision fermentation?

Precision fermentation uses a microbial host, such as a yeast or filamentous fungus, that carries a gene for a specific target protein. The microbe grows in a fermenter, secretes the protein, and the protein is then separated from the biomass and purified. The product is an ingredient, not a living culture.

How does precision fermentation differ from biomass fermentation?

In biomass fermentation the microbial cells themselves become the food, as with mycoprotein. In precision fermentation the cells are discarded after they have made a defined protein, and the purified protein is the ingredient. Traditional fermentation, by contrast, transforms whole foods using living cultures that stay in the product.

Is precision-fermented whey the same as dairy whey?

The amino acid sequence of beta-lactoglobulin can be identical to the milk protein, but small differences occur. One 2026 study found a precision-fermented version carried an extra N-terminal sequence, which gave it markedly higher stability to heat at 140 degrees Celsius. Allergen labelling still treats it as milk protein.

Are fermentation-derived proteins vegan?

They are produced without animals, so many are marketed as animal-free. Whether a product meets a vegan standard depends on the whole formulation and on how the certifier treats genetically modified production hosts. Dairy-identical proteins also still count as milk allergens, which affects labelling.

Are precision-fermented proteins genetically modified foods?

The production organism is genetically modified, while the purified ingredient may contain no viable cells and little or no recombinant DNA. EU assessment can involve both novel food and GMO procedures, as the soy leghemoglobin file shows, so the legal route depends on the product and the residues.

What is mycoprotein?

Mycoprotein is fungal biomass from Fusarium venenatum, processed into a fibrous, meat-like material. A 2019 review reports that it is sold in 17 countries and is high in protein and fibre and low in fat, cholesterol and sodium.

Can people be allergic to mycoprotein?

A small number of sensitised consumers react. A 2003 case study identified a ribosomal protein in a mould-allergic patient who reacted to mycoprotein, and a later symposium review concludes that reported allergic reactions remain exceptionally low. People with known mould allergy may wish to seek medical advice.

Which microbes are used as production hosts?

Common hosts include the yeasts Komagataella phaffii (formerly Pichia pastoris) and Saccharomyces cerevisiae, and the filamentous fungus Trichoderma reesei. Reviews also cover Yarrowia lipolytica and Kluyveromyces species. Selection depends on secretion capacity, glycosylation, productivity and regulatory familiarity.

Why is scale-up difficult?

Large fermenters face oxygen transfer limits, heat removal limits and mixing gradients that small vessels do not show, so productivity can fall when volume rises. Reviews stress titer, rate and yield, host engineering and early techno-economic analysis as the main levers for improving economics.

What purity do fermentation-derived proteins reach?

It depends on the product. The beta-lactoglobulin described in FDA GRAS Notice 863 was specified at more than 90 percent of protein on a dry matter basis, with moisture below 6 percent, ash below 3 percent and fat below 1.5 percent, and batch data showed 94 to 97 percent protein by the Dumas method.

What is leghemoglobin and why is it fermented?

Leghemoglobin is the heme-containing protein of soy root nodules. Producing it in the yeast Komagataella phaffii gives a heme source for meat analogues that supplies colour and flavour. EFSA concluded the preparation raised no safety concern at the proposed use as a colour in meat analogues.

Does the product need to carry a milk allergen warning?

Dairy-identical proteins do. The notifier of GRN 863 stated that its beta-lactoglobulin would produce a milk protein allergy and that products would declare the allergen. Egg-identical proteins would raise the corresponding egg allergen question, so every precision-fermented animal protein needs an allergen assessment.

How is precision fermentation regulated in Singapore?

Singapore defines novel food as having no significant history of use as food for at least 20 years and requires pre-market approval, with applicants submitting a safety assessment. Approval can be cancelled if the production method changes materially, so changes to strain or process need review.

What does a buyer need to ask a supplier?

Request the identity of the production strain and its safety record, the protein specification with its analytical method, residual host protein and DNA limits, allergen statements, regulatory dossiers by market, batch certificates and the process-change notification procedure. Also ask about fermenter capacity and who owns the strain.

Is fermentation capacity a bottleneck?

Reviews identify scale-up and cost as the central engineering challenges for precision fermentation, and recommend using existing fermentation infrastructure and co-location near feedstocks to lower costs. Contract manufacturing is often the practical route for early-stage products, so capacity should be agreed before launch plans are fixed.

What is Euglena and is it a protein source?

Euglena gracilis is a single-cell microalga whose dried biomass, produced by fermentation, has more than 50 percent beta-glucan according to EFSA. It is authorised in the EU as a novel food. Its main constituent is a carbohydrate, so it is not a protein ingredient.